Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BRS051
MIFTS: 59

Breast Disease

Categories: Reproductive diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Breast Disease

About this section

MalaCards integrated aliases for Breast Disease:

Name: Breast Disease 12 15 17
Breast Diseases 55 43 44 72

Classifications:

MalaCards categories:
Anatomical: Reproductive diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:3463
MeSH 44 D001941
NCIt 50 C26709
SNOMED-CT 68 79604008
UMLS 72 C0006145
Sources

Summaries for Breast Disease

About this section
MedlinePlus : 43 Most women experience breast changes at some time. Your age, hormone levels, and medicines you take may cause lumps, bumps, and discharges (fluids that are not breast milk). If you have a breast lump, pain, discharge or skin irritation, see your health care provider. Minor and serious breast problems have similar symptoms. Although many women fear cancer, most breast problems are not cancer. Some common breast changes are Fibrocystic breast changes - lumpiness, thickening and swelling, often just before a woman's period Cysts - fluid-filled lumps Fibroadenomas - solid, round, rubbery lumps that move easily when pushed, occurring most in younger women Intraductal papillomas - growths similar to warts near the nipple Blocked milk ducts Milk production when a woman is not breastfeeding NIH: National Cancer Institute

MalaCards based summary : Breast Disease, also known as breast diseases, is related to microglandular adenosis and breast fibroadenoma, and has symptoms including pruritus, exanthema and pelvic pain. An important gene associated with Breast Disease is PRLR (Prolactin Receptor), and among its related pathways/superpathways are GPCR Pathway and Circadian entrainment. The drugs Hydrocortisone and Hydrocortisone acetate have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and thyroid, and related phenotypes are endocrine/exocrine gland and homeostasis/metabolism

Disease Ontology : 12 A thoracic disease that is located in the breast.

Wikipedia : 75 Breast diseases make up a number of conditions. The most common symptoms are a breast mass, breast pain,... more...

Sources

Related Diseases for Breast Disease

About this section

Diseases related to Breast Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 296)
# Related Disease Score Top Affiliating Genes
1 microglandular adenosis 33.9 TP53 PGR ERBB2
2 breast fibroadenoma 31.5 PGR ESR1 ERBB2 CYP19A1
3 in situ carcinoma 31.3 TP53 PGR KRT5 ESR1 ERBB2 BRCA1
4 lobular neoplasia 31.2 PRLR ESR2 ESR1 ERBB2 BRCA1
5 adenocarcinoma 31.1 VEGFA TP53 ERBB2 EGF
6 insulin-like growth factor i 31.0 IGFBP3 IGF1 ESR1 EGF
7 gynecomastia 31.0 PGR ESR1 CYP19A1
8 mammary paget's disease 31.0 PGR ESR1 ERBB2
9 galactorrhea 30.9 PRLR IGF1
10 tubular adenocarcinoma 30.6 PGR ESR1 ERBB2
11 breast ductal carcinoma 30.5 TP53 TFF1 PGR ESR1 ERBB2 CTSD
12 cervical cancer 30.5 VEGFA TP53 KRT5 IGFBP3 ERBB2 CYP1A1
13 inflammatory breast carcinoma 30.4 PGR ESR1 ERBB2
14 apocrine adenocarcinoma 30.4 PGR KRT5 ESR1 ERBB2
15 meningioma, familial 30.3 VEGFA TP53 PGR ESR1
16 endometriosis 30.3 VEGFA PGR ESR2 ESR1 CYP19A1
17 estrogen excess 30.2 PGR ESR2 ESR1 CYP19A1
18 leiomyoma 30.1 PGR ESR2 ESR1 CYP19A1
19 ductal carcinoma in situ 30.1 TP53 PGR KRT5 ESR1 ERBB2 CYP19A1
20 mammographic density 30.1 PGR IGFBP3 IGF1 ESR1 CYP1B1 CYP1A1
21 prostatic hypertrophy 30.0 PGR ESR1 EGF CYP19A1
22 female breast cancer 29.9 TP53 PGR ESR1 ERBB2 CYP1A1 BRCA2
23 bilateral breast cancer 29.9 PGR ERBB2 BRCA2 BRCA1
24 hereditary breast ovarian cancer syndrome 29.9 TP53 BRCA2 BRCA1
25 breast malignant phyllodes tumor 29.7 TP53 PGR
26 sporadic breast cancer 29.7 TP53 PGR ESR2 ESR1 ERBB2 BRCA2
27 li-fraumeni syndrome 29.5 TP53 CYP19A1 BRCA2 BRCA1
28 breast cancer 29.5 VEGFA TP53 TFF1 RHOC PRLR PGR
29 fallopian tube carcinoma 29.4 VEGFA TP53 PGR ESR1 ERBB2 BRCA2
30 breast carcinoma in situ 29.3 VEGFA TP53 PGR KRT5 ESR1 ERBB2
31 ovarian disease 28.8 VEGFA TP53 PGR IGF1 ESR2 ESR1
32 rare non-malformative breast disease 12.1
33 mastitis 11.8
34 diabetic mastopathy 11.4
35 infant gynecomastia 11.3
36 breast abscess 11.3
37 hypertrophy of breast 11.2
38 multiple fibroadenomas of the breast 11.1
39 postmenopausal atrophic vaginitis 11.1 PRLR ESR2 ESR1
40 endometrial clear cell adenocarcinoma 11.0 ESR1 CTSD
41 breast squamous cell carcinoma 11.0 TP53 KRT5 ERBB2
42 slipped capital femoral epiphysis 11.0 IGFBP3 IGF1
43 hidradenocarcinoma 11.0 TP53 KRT5 ESR1 ERBB2
44 colonic disease 11.0 VEGFA TP53 ESR1 CTSD
45 tonsil cancer 11.0 TP53 KRT5 ERBB2
46 male reproductive system disease 11.0 VEGFA TP53 IGFBP3 IGF1 ESR2
47 colorectal adenoma 11.0 TP53 IGFBP3 IGF1
48 stomach disease 11.0 VEGFA TP53 TFF1 ERBB2
49 respiratory system cancer 11.0 VEGFA TP53 ERBB2 CYP1A1
50 gastrointestinal adenoma 10.9 TFF1 CYP1B1

Graphical network of the top 20 diseases related to Breast Disease:



Diseases related to Breast Disease
Sources

Symptoms & Phenotypes for Breast Disease

About this section

UMLS symptoms related to Breast Disease:


pruritus, exanthema, pelvic pain, mastodynia, breast engorgement, nipple discharge, signs and symptoms in breast, other signs and symptoms in breast, breast pain female

MGI Mouse Phenotypes related to Breast Disease:

46 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.47 BRCA1 BRCA2 COMT CTSD CYP19A1 CYP1A1
2 homeostasis/metabolism MP:0005376 10.47 BRCA1 BRCA2 COMT CTSD CYP19A1 CYP1A1
3 growth/size/body region MP:0005378 10.46 BRCA1 BRCA2 CTSD CYP19A1 CYP1A1 EGF
4 behavior/neurological MP:0005386 10.45 BRCA1 BRCA2 COMT CTSD CYP19A1 ERBB2
5 cellular MP:0005384 10.4 BRCA1 BRCA2 CTSD CYP19A1 ERBB2 ESR1
6 integument MP:0010771 10.39 BRCA1 BRCA2 CTSD CYP19A1 EGF ERBB2
7 immune system MP:0005387 10.37 BRCA1 BRCA2 COMT CTSD CYP19A1 CYP1A1
8 digestive/alimentary MP:0005381 10.36 BRCA1 BRCA2 CTSD CYP19A1 EGF ERBB2
9 cardiovascular system MP:0005385 10.34 BRCA1 COMT CYP19A1 CYP1A1 ERBB2 ESR1
10 hematopoietic system MP:0005397 10.33 BRCA1 BRCA2 COMT CTSD CYP19A1 CYP1A1
11 limbs/digits/tail MP:0005371 10.27 BRCA1 BRCA2 ERBB2 ESR1 ESR2 IGF1
12 neoplasm MP:0002006 10.25 BRCA1 BRCA2 CYP1B1 ERBB2 ESR1 ESR2
13 embryo MP:0005380 10.23 BRCA1 BRCA2 COMT ERBB2 ESR1 PGR
14 adipose tissue MP:0005375 10.21 BRCA1 CYP19A1 ESR1 ESR2 IGF1 IGFBP3
15 nervous system MP:0003631 10.18 BRCA1 BRCA2 COMT CTSD CYP19A1 ERBB2
16 muscle MP:0005369 10.16 BRCA1 CYP19A1 ERBB2 ESR1 ESR2 IGF1
17 normal MP:0002873 10.1 BRCA1 BRCA2 CYP19A1 CYP1A1 EGF ERBB2
18 liver/biliary system MP:0005370 10.02 CYP19A1 CYP1A1 ESR1 ESR2 IGFBP3 TP53
19 reproductive system MP:0005389 9.97 BRCA1 BRCA2 COMT CYP19A1 EGF ERBB2
20 no phenotypic analysis MP:0003012 9.91 CYP1A1 ESR1 ESR2 KRT5 PGR TP53
21 renal/urinary system MP:0005367 9.86 BRCA1 COMT CYP19A1 ESR1 ESR2 IGF1
22 respiratory system MP:0005388 9.56 BRCA1 COMT ERBB2 ESR1 ESR2 IGF1
23 skeleton MP:0005390 9.4 BRCA1 BRCA2 CYP19A1 ERBB2 ESR1 ESR2
Sources

Drugs & Therapeutics for Breast Disease

About this section

Drugs for Breast Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 200)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
2
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
3
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
4
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 11103-57-4, 68-26-8 9904001 445354
5 Retinol palmitate Phase 4
6 retinol Phase 4
7 Analgesics Phase 4
8 Lipid Regulating Agents Phase 4
9 Peripheral Nervous System Agents Phase 4
10 Anti-Inflammatory Agents, Non-Steroidal Phase 4
11 Analgesics, Non-Narcotic Phase 4
12 Hypolipidemic Agents Phase 4
13 Evening Primrose Phase 4
14 Central Nervous System Depressants Phase 4
15 Anesthetics, General Phase 4
16 Anesthetics, Local Phase 4
17 Anti-Inflammatory Agents Phase 4
18 Dermatologic Agents Phase 4
19 glucocorticoids Phase 4
20 Hydrocortisone 17-butyrate 21-propionate Phase 4
21 Hydrocortisone hemisuccinate Phase 4
22 Hydrocortisone-17-butyrate Phase 4
23 Respiratory System Agents Phase 4
24 Anti-Asthmatic Agents Phase 4
25 Betamethasone-17,21-dipropionate Phase 4
26 Betamethasone Valerate Phase 4 2152-44-5
27 Betamethasone sodium phosphate Phase 4
28 Betamethasone benzoate Phase 4
29 Gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate Phase 4
30 Chelating Agents Phase 4
31
Evening primrose oil Investigational, Nutraceutical Phase 4 308064-97-3
32
Propofol Approved, Investigational, Vet_approved Phase 3 2078-54-8 4943
33
Remifentanil Approved Phase 3 132875-61-7 60815
34
tannic acid Approved Phase 3 1401-55-4
35
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
36
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
37
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
38
Acetaminophen Approved Phase 3 103-90-2 1983
39
Codeine Approved, Illicit Phase 3 76-57-3 5284371
40
Ibuprofen Approved Phase 3 15687-27-1 3672
41
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
42
Mesna Approved, Investigational Phase 3 3375-50-6 598
43
Celecoxib Approved, Investigational Phase 3 169590-42-5 2662
44
Fulvestrant Approved, Investigational Phase 3 129453-61-8 104741 17756771
45
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
46
Bevacizumab Approved, Investigational Phase 3 216974-75-3
47
Lenograstim Approved, Investigational Phase 3 135968-09-1
48
Tamoxifen Approved Phase 2, Phase 3 10540-29-1 2733526
49
Docetaxel Approved, Investigational Phase 2, Phase 3 114977-28-5 148124
50
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902

Interventional clinical trials:

(show top 50) (show all 149)
# Name Status NCT ID Phase Drugs
1 A Multicenter, Randomized, Open, Parallel Controlled Clinical Study on the Efficacy and Safety of the Treatment of Cyclomastopathy With Xiaoru Sanjie Capsule Unknown status NCT02929420 Phase 4 Xiaoru Sanjie capsules;Xiao Yao pills
2 The Use of Botulinum Toxin-A in Two-stage Tissue Expander/Implant Breast Reconstruction: A Prospective, Randomized, Double-Blind Placebo Controlled Trial Unknown status NCT01427400 Phase 4 Botulinum Toxin-A;Saline
3 A Single Blinded Randomized Controlled Trial of the Comparative Effects of Tamoxifen and Evening Primrose Oil in Premenopausal Non-high Risk Patients With Benign Breast Disease With Respect to the Estrogen Receptor Status. Completed NCT00999921 Phase 4 Tamoxifen;Evening Primrose Oil
4 A Phase IV Multicentre, Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) in Combination With Exemestane, With Exploratory Epigenetic Marker Analysis Completed NCT01743560 Phase 4 RAD001;Exemestane
5 Single-shot Pectoral Plane (PECs) Blocks Versus Continuous Local Anaesthetic Infusion Analgesia or Both PECs Block and Local Anaesthetic Infusion After Non-ambulatory Breast Cancer Surgery: A Prospective, Randomised, Double-blind Trial Completed NCT03024697 Phase 4
6 Evaluation of Topical Steroids and Surgical Treatment for Idiopathic Granulomatous Mastitis Recruiting NCT02959580 Phase 4 Hydrocortisone Butyrate
7 A Randomized Controlled Study on the Effectiveness of Local Injection Combined With Topical Steroids vs. Topical Steroids Mono-therapy in the Treatment of Idiopathic Granulomatous Mastitis Recruiting NCT03766997 Phase 4 Compound Betamethasone Injection;Hydrocortisone Butyrate 0.1% Cream
8 Contrast Enhanced Breast MRI: Comparison of Two Macrocyclic Gadolinium-Based Contrast Agents: Gadoterate Meglumine (Dotarem) and Gadobutrol (Gadavist). A Prospective Study. Not yet recruiting NCT03730051 Phase 4 Gadoterate meglumine;Gadobutrol
9 A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of IoGenâ„¢ for the Treatment of Moderate or Severe, Periodic Breast Pain Associated With Symptomatic Fibrocystic Breast Disease Unknown status NCT00237523 Phase 3 IoGen (molecular iodine)
10 A Randomized Phase III Study of Metronomic vs. Intermittent Capecitabine Maintenance Therapy Following First-line Capecitabine and Docetaxel Therapy in HER2-negative Metastatic Breast Cancer Unknown status NCT01917279 Phase 3 Docetaxel plus Capecitabine;Capecitabine;Capecitabine
11 Randomized Controlled Trials of Diet and Lifestyle Intervention to Promote Chinese Postpartum Women's Health Unknown status NCT01039051 Phase 2, Phase 3
12 Randomized Pivotal Trial to Assess the Safety and Efficacy of Preoperative Focused Microwave Thermotherapy Plus Preoperative Chemotherapy Versus Preoperative Chemotherapy Alone for Cytoreduction of Large Breast Cancer in Female Patients With Intact Breast Unknown status NCT01204801 Phase 3 Chemotherapy (control)
13 Efficacy and Safety of Nutritional Supplement ONCOXIN in Patients With Breast Fibrocystic Disease Completed NCT00967681 Phase 3
14 Monitored Anesthesia Care Using Remifentanil and Ketofol Results in a Superior Quality of Recovery Compared With Total Intravenous Anesthesia in Ambulatory Breast Augmentation Completed NCT03764267 Phase 3 Remifentanil;general anesthetic
15 A Randomized Controlled Trial Comparing Combination Therapy of Acetaminophen Plus Ibuprofen Versus Tylenol #3® for the Treatment of Pain After Breast Surgery. Completed NCT00299039 Phase 3 acetaminophen plus codeine;acetaminophen plus ibuprofen
16 TARGIT: A Randomised Controlled Trial to Compare Targeted Intra-operative Radiotherapy With Conventional Post-operative Radiotherapy After Conservative Breast Surgery for Women With Early Stage Breast Cancer Completed NCT00983684 Phase 3
17 BNP7787 vs. Placebo for Prevention of Paclitaxel Neurotoxicity: A Double-Blind Multicenter Randomized Phase 3 Trial in Patients With Metastatic Breast Cancer Completed NCT00039780 Phase 3 BNP7787;Placebo
18 Botulinum Toxin A in Tissue Expander Breast Reconstruction: A Double-Blinded Randomized Controlled Trial Completed NCT01591746 Phase 3 Botulinum Toxin Type A;Sodium Chloride Solution
19 A Phase III Multicentre Double Blind Randomised Trial of Celecoxib Versus Placebo in Primary Breast Cancer Patients Completed NCT02429427 Phase 3 Celecoxib
20 A Randomized Double-blind, Placebo-controlled Study of Ribociclib in Combination With Fulvestrant for the Treatment of Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer Who Have Received no or Only One Line of Prior Endocrine Treatment Active, not recruiting NCT02422615 Phase 3 Ribociclib;fulvestrant;Ribociclib placebo
21 A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer Active, not recruiting NCT00887536 Phase 3 bevacizumab;docetaxel;doxorubicin;cyclophosphamide;pegfilgrastim
22 Prospective Randomized Controlled Study on the Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer Not yet recruiting NCT03373708 Phase 2, Phase 3 Epirubicin;Cyclophosphamide;Docetaxel;Goserelin acetate;Tamoxifen;Letrozole
23 The Efficacy and Molecular Mechanism of Botulinum Toxin in the Reduction of Breast Reduction Mammoplasty Scar Formation: A Prospective, Controlled, Randomized, Double-blinded Study Not yet recruiting NCT03887377 Phase 2, Phase 3 Botulinum Toxins;Normal saline
24 A Multicenter Phase II Study of Docosahexaenoic Acid (DHA) in Patients With a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease Unknown status NCT01849250 Phase 2 Docosahexaenoic Acid
25 A Randomized Pivotal Clinical Trial In Breast Cancer Patients Of Pre-Operative Focal Microwave Thermotherapy Treatment For Early-Stage Breast Disease In Intact Breast Unknown status NCT00036998 Phase 2
26 A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Multicenter Evaluation of the Use of Topically Administered Danazol Versus Placebo in Subjects With Pain Associated With Fibrocystic Breast Disease Completed NCT00744276 Phase 2 danazol;Placebo
27 A Multicenter, Open-label, Parallel, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of LuminoMark Inj. (Conc. for Fluorescence) Localization in Patients With Nonpalpable Breast Lesions Completed NCT03743259 Phase 2 LuminoMark inj. 0.1mL;LuminoMark inj. 0.2mL;Charcotrace Inj.
28 An Open-Label, MultiCenter Evaluation of the Use of Topically Administered FP1198 in Subjects With Pain Associated With Cyclic Mastalgia Completed NCT01105793 Phase 2 Danazol
29 Phase II Clinical Trial of Neoadjuvant Treatment With Zolendronic Acid Plus Anthracycline and Taxane in Locally Advanced Breast Cancer Completed NCT01472146 Phase 2 Zo-Nantax
30 A Phase 2 Study of ET-743 in Subjects With Advanced Breast Cancer Completed NCT00050427 Phase 2 ET743;ET743
31 A Randomized, Placebo-Controlled, Parallel Treatment Group, Double-Masked Study to Evaluate the Efficacy and Safety of Two Doses of Oral DMI-5207 in Adult Subjects With Diabetic Macular Edema Completed NCT02002403 Phase 2 Danazol
32 Phase II Study of Soy Protein to Treat Vasomotor Symptoms in Postmenopausal Women Taking Tamoxifen Completed NCT00031720 Phase 2 Tamoxifen
33 Guaraná ("Paullinia Cupana") for Chemotherapy Related Fatigue in Breast Cancer Patients: Results Of A Pilot Double Blind Randomized Study Completed NCT01043913 Phase 2 Guarana extract
34 TARGIT-E(Elderly) Prospective Phase II Study of Intraoperative Radiotherapy (IORT) in Elderly Patients With Small Breast Cancer Completed NCT01299987 Phase 2
35 A Randomized, Double-Blind Trial, Comparing the Safety in Mothers and Their Infants and Immunogenicity in Mothers of Live Attenuated Influenza Vaccine (LAIV) to Inactivated Trivalent Influenza Vaccine (TIV) When Administered to Breast Feeding Women Completed NCT01181323 Phase 2
36 Analgesic Efficacy of Pulsed Radiofrequency in Non-cyclic Mastalgia Completed NCT03715413 Phase 2 Tamoxifen
37 A Randomized Phase II Prevention Trial in Subjects at High Risk for Hormone Non-responsive Breast Cancer Completed NCT01500577 Phase 2 nimesulide;Simvastatin
38 TBCRC 042 - A Randomized Phase II Window-of-Opportunity Trial of Ruxolitinib in Patients With High Risk and Premalignant Breast Conditions Recruiting NCT02928978 Phase 2 Ruxolitinib;Placebo (for Ruxolitinib)
39 Circadian Thermal Sensing for the Detection of Breast Disease as a Supplemental Cancer Screening System Recruiting NCT02511301 Phase 1, Phase 2
40 A Phase I/II Trial of Leflunomide in Women With Previously Treated Metastatic Triple Negative Cancers Recruiting NCT03709446 Phase 1, Phase 2 Leflunomide
41 A Multicenter, Phase I/II Trial of Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HeR-positive, Her2-positive Metastatic Breast Cancer Recruiting NCT03304080 Phase 1, Phase 2 Anastrozole;Palbociclib;Trastuzumab;Pertuzumab
42 A Randomized, Multicenter, Phase II Study of the Efficacy and Safety of Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Recruiting NCT03500380 Phase 2 RC48-ADC;Lapatinib;Capecitabine
43 Vaginal Progesterone Versus Placebo for the Treatment of Vaginal Atrophy - a Double Blind Randomized Control Trial Recruiting NCT02460302 Phase 2 Vaginal progesterone;Placebo
44 A Randomized, Open-label Study of First Line Pyrotinib, Trastuzumab With an Aromatase Inhibitors, in the Treatment of HER2 Positive and HR Positive Metastatic or Inoperable Locally Advanced Breast Cancer Not yet recruiting NCT03910712 Phase 2 Pyrotinib;Trastuzumab;Aromatase inhibitor
45 Window Trial of Abemaciclib for Surgically Resectable, Chemotherapy-Resistant, Triple Negative Breast Cancer (a BEAUTY Study*) Not yet recruiting NCT03979508 Phase 2 Abemaciclib
46 Identifying the miR Fingerprint in NAF, Serum, and Tissue in Patients With Ductal Carcinoma in Situ (DCIS) or Invasive Breast Cancer Suspended NCT02127073 Phase 2 Intranasal Oxytocin
47 GCC 0901- A Phase II Study of Letrozole in Combination With Lapatinib Followed by an Addition of Everolimus in Postmenopausal Women With Advanced Endocrine Resistant Breast Cancer Terminated NCT01499160 Phase 2 letrozole;lapatinib;everolimus
48 A Randomized Phase 2, Open-Label Study Of CP-751,871 In Combination With Docetaxel And Docetaxel Alone As A First Line Treatment Of Patients With Advanced Breast Cancer Withdrawn NCT00678626 Phase 2 CP-751,871;Docetaxel
49 A Phase 1 Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors Completed NCT02897778 Phase 1 Entinostat
50 A Phase I Investigation of the Safety, Tolerability and Immunogenicity of V934/V935 hTERT Vaccination in Cancer Patients With Selected Solid Tumors Completed NCT00753415 Phase 1

Search NIH Clinical Center for Breast Disease

Cochrane evidence based reviews: breast diseases

Sources

Genetic Tests for Breast Disease

About this section
Sources

Anatomical Context for Breast Disease

About this section

MalaCards organs/tissues related to Breast Disease:

41
Breast, Lymph Node, Thyroid, Testes, Skin, Prostate, Bone

The Foundational Model of Anatomy Ontology organs/tissues related to Breast Disease:

19
Breast
Sources

Publications for Breast Disease

About this section

Articles related to Breast Disease:

(show top 50) (show all 4634)
# Title Authors PMID Year
1
Contrast ultrasound versus ultrasound elastography for diagnosis of breast lumps: A cross-sectional study. 17
31261536 2019
2
Surgical Management of Gynecomastia: A Review of the Current Insurance Coverage Criteria. 17
31033818 2019
3
Strain histograms used for differential diagnosis of breast masses according to hardness percentage. 17
30985674 2019
4
Expression of estrogenicity genes in a lineage cell culture model of human breast cancer progression. 9 38
19308726 2010
5
Genetic variation and circulating levels of IGF-I and IGFBP-3 in relation to risk of proliferative benign breast disease. 9 38
19551864 2010
6
Cells with minimal expression of the JAK/STAT pathway related proteins STAT5a and the prolactin receptor: evidence of an alternate prolactin receptor isoform in breast disease. 9 38
20214633 2010
7
Nipple aspirate fluid collection, related factors and relationship between carcinoembryonic antigen in nipple aspirate fluid and breast diseases in women in Harbin, PRC. 9 38
19273481 2009
8
Estrogen alpha and progesterone receptor expression in the normal mammary epithelium in relation to breast cancer risk. 9 38
18798271 2009
9
Caffeine consumption and the risk of breast cancer in a large prospective cohort of women. 9 38
18852405 2008
10
[mRNA expression of CK19 and CEA in peripheral blood of patients with breast cancer detected by real-time quantitative PCR]. 9 38
19087676 2008
11
The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified. 9 38
17851763 2008
12
Quantitative detection of methylated ESR1 and 14-3-3-sigma gene promoters in serum as candidate biomarkers for diagnosis of breast cancer and evaluation of treatment efficacy. 9 38
18379196 2008
13
A comparison of plasma versus histologic indices of angiogenic markers in breast cancer. 9 38
18091379 2007
14
Importance of novel sequence alterations in the FHIT gene on formation of breast cancer. 9 38
18338496 2007
15
[Analysis of the mutation of BRCA1 gene in 70 Uigur women breast cancer patients in Xinjiang]. 9 38
17557253 2007
16
Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. 9 38
17417639 2007
17
Clinical utility of serum human epidermal receptor-2/neu detection in breast cancer patients. 9 38
17431282 2007
18
IGFBP3 mRNA expression in benign and malignant breast tumors. 9 38
17210081 2007
19
The expression of FHIT, PCNA and EGFR in benign and malignant breast lesions. 9 38
17164758 2007
20
[Role of immunocytochemistry in fine needle aspiration cytology diagnosis of mammary lesions of breast]. 9 38
17374259 2006
21
Polymorphisms in estrogen-metabolizing and estrogen receptor genes and the risk of developing breast cancer among a cohort of women with benign breast disease. 9 38
16808847 2006
22
Hormones and progeny of breast tumor cells. 9 38
16698656 2006
23
Prognostic significance of estrogen receptor Beta in epithelial hyperplasia of usual type with known outcome. 9 38
16327431 2005
24
[Expression and clinical significance of cytokeratin 19 in bone marrow of patients with breast cancer]. 9 38
15946491 2005
25
Detection of tumor markers including carcinoembryonic antigen, APC, and cyclin D2 in fine-needle aspiration fluid of breast. 9 38
15508191 2004
26
Insulin-like growth factor (IGF)-I and IGF-II serum concentrations in patients with benign and malignant breast lesions: free IGF-II is correlated with breast cancer size. 9 38
15217931 2004
27
p65 and c-erbB2 genes expression in breast tumors: comparison with some histological typing, grading and clinical staging. 9 38
12866575 2003
28
Clustering of variations and haplotype analysis in the highly variable region of exon 11 of BRCA1 in Chinese women with sporadic breast cancer. 9 38
12402341 2002
29
Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability. 9 38
11839578 2002
30
Behaviour of estrogen receptor, histological correlation, and clinical outcome in patients with benign breast disorders. 9 38
12699101 2002
31
Breast cancer risk factors and HER2 over-expression in tumors. 9 38
12132871 2001
32
Association between estradiol, estrogen receptors, total lipids, triglycerides, and cholesterol in patients with benign and malignant breast tumors. 9 38
11282289 2000
33
Serum c-erbB-2 protein in breast cancer patients. 9 38
10998842 2000
34
Dissociated overexpression of cathepsin D and estrogen receptor alpha in preinvasive mammary tumors. 9 38
10836299 2000
35
Breast cancer, heterocyclic aromatic amines from meat and N-acetyltransferase 2 genotype. 9 38
10753193 2000
36
RT-PCR amplification of CK19 mRNA in the blood of breast cancer patients: correlation with established prognostic parameters. 9 38
10845277 2000
37
Tissue iodine content and serum-mediated 125I uptake-blocking activity in breast cancer. 9 38
10720070 2000
38
Analysis of cathepsin D in human breast cancer: usefulness of the processed 31 kDa active form of the enzyme as a prognostic indicator in node-negative and node-positive patients. 9 38
10845280 2000
39
HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer. 9 38
10637239 2000
40
The normal breast epithelium of women with breast cancer displays an aberrant response to estradiol. 9 38
10548314 1999
41
Angiogenic growth factors in preinvasive breast disease. 9 38
10537355 1999
42
HER-2/neu (c-erb-B2) gene and protein in breast cancer. 9 38
10396301 1999
43
Serum levels of insulin-like growth factor binding protein-3 in benign and malignant breast disease. 9 38
10442920 1999
44
Receiver-operating characteristic (ROC) curve analysis of cathepsin D and pS2 in breast disease; results from a prospective study. 9 38
10629636 1999
45
Reduced Fhit expression in sporadic and BRCA2-linked breast carcinomas. 9 38
10363992 1999
46
Environmental exposure to hexachlorobenzene (HCB) and risk of female breast cancer in Connecticut. 9 38
10350435 1999
47
[Relationship of estrogen and progesterone receptors to the menstrual cycle and menopausal status at the time of breast surgery]. 9 38
10486879 1999
48
Transcriptional activation of functional endogenous estrogen receptor gene expression in MCF10AT cells: a model for early breast cancer. 9 38
9772278 1998
49
c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value. 9 38
9879773 1998
50
Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk. 9 38
9731732 1998
Sources

Variations for Breast Disease

About this section
Sources

Expression for Breast Disease

About this section
Search GEO for disease gene expression data for Breast Disease.
Sources

Pathways for Breast Disease

About this section

Pathways related to Breast Disease according to GeneCards Suite gene sharing:

(show all 40)
# Super pathways Score Top Affiliating Genes
1
GPCR Pathway 64
Show member pathways
 13.69 VEGFA TP53 RHOC IGF1 ESR2 ESR1
2
Circadian entrainment 37
Show member pathways
 12.99 VEGFA TFF1 PGR ESR2 ESR1 CTSD
3
PI3K-Akt signaling pathway 37
Show member pathways
 12.94 VEGFA TP53 PRLR IGF1 ERBB2 EGF
4
Endometrial cancer 37
Show member pathways
 12.83 VEGFA TP53 IGF1 ERBB2 EGF BRCA2
5
MAPK signaling pathway 37 1
12.72 VEGFA TP53 IGF1 ERBB2 EGF
6
Chks in Checkpoint Regulation 64
Show member pathways
 12.65 TP53 IGF1 ESR2 ESR1 BRCA2 BRCA1
7
Pathways in cancer 37
12.58 VEGFA TP53 IGF1 ESR2 ESR1 ERBB2
8
ErbB signaling pathway 37 1
Show member pathways
 12.54 VEGFA TP53 ERBB2 EGF
9
MicroRNAs in cancer 37
12.49 VEGFA TP53 ERBB2 CYP1B1 BRCA1
10
Prolactin Signaling Pathway 1 37
Show member pathways
 12.45 PRLR ESR2 ESR1 ERBB2 CTSD
11
DNA Damage Response 1
Show member pathways
 12.34 TP53 IGFBP3 IGF1 BRCA1
12
Proteoglycans in cancer 37
12.26 VEGFA TP53 IGF1 ESR1 ERBB2
13
Glioma 37
Show member pathways
 12.2 VEGFA TP53 IGF1 ESR2 ESR1 ERBB2
14
Development Ligand-independent activation of ESR1 and ESR2 22
Show member pathways
 12.17 TFF1 IGF1 ESR2 ESR1 ERBB2 EGF
15
Glioblastoma Multiforme 64
11.94 TP53 RHOC IGF1 EGF
16
Gastric cancer 37
Show member pathways
 11.94 TP53 PGR IGF1 ESR2 ESR1 ERBB2
17
HIF-1 signaling pathway 37
11.92 VEGFA IGF1 ERBB2 EGF
18
Signaling by ERBB4 66
Show member pathways
 11.89 PRLR PGR ESR1 ERBB2 EGF
19
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors 66
Show member pathways
 11.82 VEGFA ESR1 ERBB2
20
Integrated Breast Cancer Pathway 1
11.82 VEGFA TP53 ESR1 CYP19A1 BRCA2 BRCA1
21
Nuclear Receptor transcription pathway 66
Show member pathways
 11.81 PGR ESR2 ESR1
22
BRCA1 Pathway 64
Show member pathways
 11.77 TP53 BRCA2 BRCA1
23
Neural Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.74 VEGFA IGF1 EGF
24
Platinum drug resistance 37
11.7 TP53 ERBB2 BRCA1
25
Bladder cancer 37 1
11.7 VEGFA TP53 ERBB2 EGF
26
Transcription Ligand-dependent activation of the ESR1/SP pathway 22
Show member pathways
 11.68 VEGFA PRLR ESR1
27
Pathways Affected in Adenoid Cystic Carcinoma 1
11.65 TP53 ERBB2 BRCA1
28
Steroid hormone biosynthesis 37
Show member pathways
 11.64 CYP1B1 CYP1A1 CYP19A1 COMT
29
Androstenedione and testosterone biosynthesis and metabolism p.1 22
Show member pathways
 11.56 CYP1A1 CYP19A1 COMT
30
Hepatitis C and Hepatocellular Carcinoma 1
11.53 VEGFA TP53 BRCA1
31
Differentiation Pathway 1
11.49 VEGFA IGF1 EGF
32
Ovarian steroidogenesis 37
11.49 IGF1 CYP1B1 CYP1A1 CYP19A1
33
FOXA1 transcription factor network 1
Show member pathways
 11.47 TFF1 ESR1 BRCA1
34
Aryl Hydrocarbon Receptor 1
11.46 VEGFA ESR1 CYP1B1 CYP1A1
35
LKB1 signaling events 1
11.43 TP53 ESR1 CTSD
36
Photodynamic therapy-induced HIF-1 survival signaling 1
11.36 VEGFA TP53 IGFBP3
37
Estrogen metabolism 1
Show member pathways
 11.27 CYP1B1 CYP1A1 CYP19A1 COMT
38
Ovarian Infertility Genes 1
11.21 PRLR PGR ESR2 CYP19A1
39
Estrogen Receptor Pathway 1
10.8 ESR1 CYP1B1 CYP1A1
40
Aromatase Inhibitor Pathway (Breast Cell), Pharmacodynamics 61
10.1 ESR2 ESR1 CYP19A1
Sources

GO Terms for Breast Disease

About this section

Cellular components related to Breast Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 platelet alpha granule lumen GO:0031093 9.33 VEGFA IGF1 EGF
2 insulin-like growth factor ternary complex GO:0042567 8.96 IGFBP3 IGF1
3 insulin-like growth factor binding protein complex GO:0016942 8.62 IGFBP3 IGF1

Biological processes related to Breast Disease according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 regulation of apoptotic process GO:0042981 9.9 TP53 IGFBP3 ESR1 BRCA1
2 negative regulation of gene expression GO:0010629 9.87 VEGFA PGR IGF1 ESR1
3 positive regulation of cell migration GO:0030335 9.85 VEGFA RHOC IGF1 EGF
4 cell proliferation GO:0008283 9.73 TP53 IGF1 CYP1A1 BRCA2
5 positive regulation of gene expression GO:0010628 9.73 VEGFA TP53 IGF1 ERBB2 EGF BRCA1
6 response to estrogen GO:0043627 9.69 ESR1 COMT BRCA1
7 positive regulation of MAP kinase activity GO:0043406 9.67 VEGFA ERBB2 EGF
8 positive regulation of epithelial cell proliferation GO:0050679 9.65 VEGFA IGF1 ERBB2
9 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.62 VEGFA TP53 IGF1 EGF
10 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.59 IGFBP3 IGF1
11 estrogen metabolic process GO:0008210 9.58 CYP1B1 COMT
12 activation of transmembrane receptor protein tyrosine kinase activity GO:0007171 9.58 PRLR EGF
13 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.56 TP53 ESR1
14 omega-hydroxylase P450 pathway GO:0097267 9.54 CYP1B1 CYP1A1
15 toxin metabolic process GO:0009404 9.52 CYP1B1 CYP1A1
16 positive regulation of transcription, DNA-templated GO:0045893 9.5 TP53 IGF1 ESR2 ESR1 EGF BRCA2
17 negative regulation of ERBB signaling pathway GO:1901185 9.46 ERBB2 EGF
18 chordate embryonic development GO:0043009 9.4 BRCA2 BRCA1
19 mammary gland development GO:0030879 9.37 PGR CYP19A1
20 mammary gland alveolus development GO:0060749 9.33 VEGFA ESR1 EGF
21 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.8 TP53 BRCA2 BRCA1

Molecular functions related to Breast Disease according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.8 VEGFA TFF1 IGF1 EGF
2 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.72 CYP1B1 CYP1A1 CYP19A1
3 monooxygenase activity GO:0004497 9.7 CYP1B1 CYP1A1 CYP19A1
4 steroid hormone receptor activity GO:0003707 9.69 PGR ESR2 ESR1
5 nuclear receptor activity GO:0004879 9.63 PGR ESR2 ESR1
6 oxygen binding GO:0019825 9.58 CYP1B1 CYP1A1 CYP19A1
7 identical protein binding GO:0042802 9.56 VEGFA TP53 PGR ESR2 ESR1 ERBB2
8 steroid binding GO:0005496 9.54 PGR ESR2 ESR1
9 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen GO:0016712 9.5 CYP1B1 CYP1A1 CYP19A1
10 estrogen receptor activity GO:0030284 9.48 ESR2 ESR1
11 estrogen response element binding GO:0034056 9.43 ESR2 ESR1
12 aromatase activity GO:0070330 9.33 CYP1B1 CYP1A1 CYP19A1
13 enzyme binding GO:0019899 9.1 TP53 PGR ESR2 ESR1 CYP1A1 BRCA1
14 metal ion binding GO:0046872 10.28 TP53 PRLR PGR IGFBP3 ESR2 ESR1
15 protein binding GO:0005515 10.21 VEGFA TP53 TFF1 RHOC PRLR PGR
Sources

Sources for Breast Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....